Basit öğe kaydını göster

Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

dc.contributor.authorÜNAL, ŞULE
dc.contributor.authorKARAKAŞ, Zeynep
dc.contributor.authorAlbayrak, Meryem
dc.contributor.authorOzdemir, Gul Nihal
dc.contributor.authorKocak, Ulker
dc.contributor.authorOzbek, Namik Yasar
dc.contributor.authorYozgat, Ayca Koca
dc.contributor.authorLEBLEBİSATAN, GÖKSEL
dc.contributor.authorAkbayram, Sinan
dc.contributor.authorOzel, Simge Cinar
dc.contributor.authorERDURAN, EROL
dc.contributor.authorYilmaz, Sebnem
dc.contributor.authorUnuvar, Aysegul
dc.contributor.authorOren, Hale
dc.contributor.authorYarali, Nese
dc.contributor.authorSasmaz, Ilgen
dc.contributor.authorCelkan, Tiraje
dc.contributor.authorKaraman, Serap
dc.contributor.authorMalbora, Baris
dc.contributor.authorTokgoz, Huseyin
dc.contributor.authorGokcebay, Dilek Gurlek
dc.contributor.authorSoker, Murat
dc.contributor.authorCakmakli, Hasan Fatih
dc.contributor.authorBor, Ozcan
dc.contributor.authorOymak, Yesim
dc.contributor.authorZengin, Emine
dc.date.accessioned2021-03-04T14:48:19Z
dc.date.available2021-03-04T14:48:19Z
dc.date.issued2020
dc.identifier.citationYozgat A. K. , LEBLEBİSATAN G., Akbayram S., Ozel S. C. , KARAKAŞ Z., ERDURAN E., Yilmaz S., Kocak U., ÜNAL Ş., Ozdemir G. N. , et al., "Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey", TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.3, ss.139-144, 2020
dc.identifier.issn1300-7777
dc.identifier.othervv_1032021
dc.identifier.otherav_836e9152-cc68-4c1c-8951-e9424b98da2f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/89467
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2020.2019.0380
dc.description.abstractObjective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectHematoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp
dc.titleOutcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey
dc.typeMakale
dc.relation.journalTURKISH JOURNAL OF HEMATOLOGY
dc.contributor.departmentCity Hospital Ankara , ,
dc.identifier.volume37
dc.identifier.issue3
dc.identifier.startpage139
dc.identifier.endpage144
dc.contributor.firstauthorID2250128


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster